Avacta

@avacta

We develop safe and efficacious drugs, and powerful research and diagnostic tools, based on our proprietary Affimer® and pre|CISION platforms.

United Kingdom
Vrijeme pridruživanja: siječanj 2014.

Tweetovi

Blokirali ste korisnika/cu @avacta

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @avacta

  1. proslijedio/la je Tweet
    4. velj
    Poništi
  2. proslijedio/la je Tweet
    4. velj

    members are exhibiting Middle East in Dubai until Thursday, go and visit them on stand Z1.B47

    Poništi
  3. proslijedio/la je Tweet
    4. velj

    Avacta Group agreement with AffyXell - -

    Poništi
  4. 4. velj

    Alastair Smith provides update on AffyXell collaboration and licence agreement.

    Poništi
  5. 3. velj

    We are exhibiting at MEDLAB Middle East this week. Come along to Stand Z1.B47 to find out how Affimer proteins can transform your immunoassay.

    Poništi
  6. 3. velj

    Avacta and Daewoong Agree Collaboration and License Agreement with AffyXell Therapeutics.

    Poništi
  7. proslijedio/la je Tweet
    30. sij

    Just posted: Avacta - It Gets Even Better

    Poništi
  8. 29. sij

    Malcolm Stacey reiterates his excitement about Avacta Group as a priority penny share that he tipped recently for 2020.

    Poništi
  9. proslijedio/la je Tweet
    28. sij
    Poništi
  10. proslijedio/la je Tweet
    29. sij

    CEO INTERVIEW: Avacta Group PoC for proprietary new class of anti-cancer therapy - -

    Poništi
  11. 28. sij

    In this short video, Avacta’s Chief Executive Officer Alastair Smith explains the TMAC® drug conjugate and the recent data from the lead molecule in that programme.

    Poništi
  12. proslijedio/la je Tweet
    28. sij
    Poništi
  13. proslijedio/la je Tweet
    28. sij
    Poništi
  14. 28. sij

    Successful initial proof-of-concept for a proprietary new class of anti-cancer therapy: Avacta’s first TMAC drug conjugate molecule shown to out-perform avelumab in an animal model.

    Poništi
  15. 27. sij

    New paper published in showcasing the Affimer technology: "Harnessing anti-idiotypic antibody alternatives to advance biotherapeutic pharmacokinetic assays"

    Poništi
  16. 24. sij

    Given the high level of interest we experienced during the JP Morgan Healthcare Week, we would certainly agree that immuno-oncology is at the top of large pharma’s priorities and shopping lists.

    Poništi
  17. 24. sij

    In this interview, Avacta CEO Alastair Smith discusses the trading update for the period ended 31 December 2019. .

    Poništi
  18. proslijedio/la je Tweet
    23. sij

    Avacta Group has forecasted continued growth into 2020 as the group revealed its order intake and sales pipeline to be ‘the strongest to date’. Read the full announcement here:

    Poništi
  19. 23. sij

    New research on Avacta published by : 'Positive 17-month trading update'.

    Poništi
  20. 23. sij

    Trading update: Strong revenue growth and cash position.

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·